Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib maintenance after TACE for unresectable or recurrent hepatocellular carcinoma
ChiCTR1800017511Phase 4Recruiting
- Sponsor
- Chongqing University Cancer Hospital
- Start
- Aug 2018
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib in hepatocellular carcinoma (HCC), sponsored by Chongqing University Cancer Hospital. Primary endpoints: Overall survival and Disease control rate. Started Aug 2018; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR1800017511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800017511.